Clinical Trial

Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 1, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until disease progression or intolerable toxicity or patients withdrawal of consent,and the target sample size is 60 individuals.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04483284
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Hepatocellular Carcinoma
Enrollment 28 participants
Start Date 2020-06-24
Primary Completion 2024-12 (estimated)
Study Completion 2025-05 (estimated)
Updated on ClinicalTrials.gov 2024-08-01